Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳

Arndt Vogel· @ArndtVogel · X·2026-10-23 22:26· 2 天前评分70

正文 · 原文

Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳
#ESMO26 #ESMOAmbassadors
👉 ORR: 56 vs 13%
👉 mOS: 19.6 vs 9.7 mo
👉no unexpected safety signal
🧐Supports sequential targeting of Her2
@myESMO @ASCO

921 浏览 · 18 赞 · 7 转发 · 0 回复

会议摘要

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

LBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上

Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE

https://esmocongress.esmo.org

来源：Arndt Vogel · x.com